Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.25 - $170.47
Previous CloseN/A
Volume7.58M
Average Volume (3M)13.31M
Market Cap
$12.70B
Enterprise Value$21.15B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.36
Next Earnings
May 01, 2025EPS Estimate
-3.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.28
Shares Outstanding384,817,800
10 Day Avg. Volume13,922,052
30 Day Avg. Volume13,312,262
Standard Deviation0.27
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.51
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.82
Enterprise Value/Ebitda-10.23
Forecast
1Y Price Target
$45.14Price Target Upside25.74% Upside
Rating ConsensusHold
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe company expects a $1 billion reduction in cash costs from 2024 to 2025, which contributes to the goal of cash breakeven by 2028.
Product ApprovalsThe company highlighted its expectation of receiving approvals for three products, including a next-gen COVID-19 vaccine and an RSV vaccine for high-risk adults.
Bears Say
Regulatory ChallengesModerna's Norovirus pivotal program received an FDA clinical hold due to a GBS case, a new finding.
Revenue DependenceThe company’s near- and intermediate-term prospects are still largely tied to COVID revenue streams, which are considered problematic due to forecasting difficulty.
---
Ownership Overview
18.62% Insiders
20.00% Mutual Funds
21.37% Other Institutional Investors
17.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $29.25 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $12.70B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 01, 2025 which is in 70 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 14, 2025. The company reported -$2.91 earnings per share for the quarter, missing the consensus estimate of -$2.68 by -$0.23.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -3.02.
How many shares outstanding does Moderna have?
Moderna has 384,817,800 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.91 in its last earnings report, missing expectations of -$2.68. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
---
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.14 (25.74% Upside)
$45.14 (25.74% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.54%
12-Months-Change
Fundamentals
Return on Equity
-18.65%
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Moderna's earnings call reflected a challenging year with significant revenue declines and net losses. However, the company demonstrated strong cost-saving measures and maintained a substantial cash position. Progress in the product pipeline and operational efficiency goals offer potential for future growth.Read More>---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$45.14
▲(25.74% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
34/41 ratings generated profit
1 Year Average Return
-3.75%
reiterated a sell rating 17 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 82.93% of your transactions generating a profit, with an average return of -3.75% per trade.
---